SNAI1 is a zinc-finger transcriptional repressor that serves as a master regulator of epithelial-to-mesenchymal transition (EMT) and related developmental processes. It binds E-boxes in the promoters of CDH1, CLDN7, and KRT8, recruiting the histone demethylase KDM1A to suppress transcription through altered histone methylation patterns. During EMT, SNAI1 coordinates with LOXL2 to remodel pericentromeric heterochromatin, facilitating the acquisition of mesenchymal traits. SNAI1 dysregulation is implicated in multiple malignancies. In thymic epithelial tumors, SNAI1 promotes EMT and cancer stem cell properties through the PIK3R2/p-EphA2 axis 1. In lung cancer, UGDH-mediated stabilization of SNAI1 mRNA accelerates metastasis 2, while in pancreatic cancer, BMP-mediated suppression of SNAI1 maintains epithelial cell populations and cellular heterogeneity 3. SNAI1 expression also correlates with adverse outcomes in cervical cancer, where HPV16/18 E7 protein upregulates SNAI1 to suppress CDH1 4. Recent studies reveal additional layers of SNAI1 regulation and function. A SNAI1 enhancer RNA (SNAI1e) drives SNAI1 expression and enforces TGF-β/SMAD signaling, promoting EMT, stemness, and chemotherapy resistance in breast cancer 5. SNAI1 also mediates endothelial-to-mesenchymal transition in pathological contexts including extracranial arteriovenous malformations 6 and pulmonary arterial hypertension, where TGF-β1-induced SNAI1 upregulation depends on calcium signaling 7. Targeting SNAI1 or its regulatory pathways represents a promising therapeutic strategy across multiple disease contexts.